Tests valsartan, a blood pressure drug, for pulmonary arterial hypertension
Tests valsartan against a placebo in adults with pulmonary arterial hypertension.
Plain-language title generated from the registry record
Registry title: Repurposing Valsartan May Protect Against Pulmonary Hypertension
Key facts
- Where
- Seattle, United StatesSee the site
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT06053580, who can take part
Where in United States
- University of Washington Medical CenterSeattle, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University of Washington
- Trial code
- NCT06053580
- Record updated
- 4 May 2026
- Original description
This is a Phase 2, single-center, randomized placebo controlled trial of valsartan (an angiotensin receptor blocker) in adults with pulmonary arterial hypertension. The study will evaluate the safety and clinical efficacy of a 24-week course of valsartan.Read full original descriptionShow less
Repurposing Valsartan May Protect Against Pulmonary Hypertension
This is a Phase 2, single-center, randomized placebo controlled trial of valsartan (an angiotensin receptor blocker) in adults with pulmonary arterial hypertension. The study will evaluate the safety and clinical efficacy of a 24-week course of valsartan.
Inclusion: Male or female, age 18 to 80; WHO Group 1 Pulmonary Arterial Hypertension; NYHA Functional Class II, III, or IV at screening (Appendix 2 for Functional Class Decision Aid); Right heart catheterization within five years demonstrating a mean pulmonary arterial pressure of ≥25 mmHg, occlusion pressure of ≤15 mmHg, and resistance ≥ 3 wood units; Participants with a right heart catheterization within five years demonstrating a mean pulmonary arterial pressure of ≥ 25 mmHg and occlusion pressure of 15 - 20 mmHg will be considered for inclusion if the pulmonary vascular resistance ≥ 9 wood units and they are being treated with pulmonary arterial hypertension specific therapy; Able to walk with/without a walking aid for a distance of at least 50 meters.
Exclusion: Has received or will receive an investigational drug, device, or study within 30 days or during the course of study; ACE-inhibitor, ARB or ARNI use within 30 days of randomization; Anticipated survival less than 1 year due to concomitant disease; Non-group 1 pulmonary hypertension or veno-occlusive disease; History of interstitial lung disease, unless subject has collagen vascular disease and has pulmonary function testing conducted within 12 months demonstrating a total lung capacity or vital capacity of ≥ 60 %; Allergy or angioedema with ACE-inhibitor use; Left sided myocardial disease as evidenced by left ventricular ejection fraction < 40%; Any other clinically significant illness or abnormal laboratory values (measured during the Screening period) that, in the opinion of the Investigator, might put the subject at risk of harm during the study or might adversely affect the interpretation of the study data; Potassium >5mEq/L or sCr >2mg/dL at screening; Pregnant or lactating; SBP <90mmHg at screening.